Skip to main content

Gout

Gout Journal Club https://t.co/noYxFJsrFD

Dr. John Cush @RheumNow( View Tweet )

Long term F/U of Gout (CARES) trial (febuxostat vs allopurinol) shows remission increased from 37% (1,593/4,259) 1st Yr to 63% (322/510) at year 6. Over the 6 years, ~60 achieved remission at least once; more likely based on age, race, dz severity, comorbidities, & febuxostat

Dr. John Cush @RheumNow( View Tweet )

Chinese target trial emulation of 2092 adults with stage G3–G4 CKD & asymptomatic hyperuricemia starting ULT. At 3 yrs, renal progression (ESKD or ≥40% eGFR decline) was 33.3% in T2T vs 35.8% in non-T2T (risk ratio 0.93; 0.83–1.08). https://t.co/lAT0noE1uA https://t.co/mFVpvvFcsN
Dr. John Cush @RheumNow( View Tweet )
Cochicine overdose still occurs & can be deadly. There is no antidote. From 2011-2021, there were 57 pediatric cases (median 7 yrs)(0.41 /million kids/year. 52% started w/ GI Sxs, 12% multiple organ failure &4 deaths (7%). Ingested doses ranged from 0.01 to 1.45 mg/kg. https://t.co/RULmdBX0Qj
Dr. John Cush @RheumNow( View Tweet )
RHEUM SURVEY>> Which Gout drugs lower the risk of cardiovascular death? Answer here: https://t.co/1OY1B3ET7B https://t.co/MRJP5OOtXb
Dr. John Cush @RheumNow( View Tweet )
ICYMI: Worldwide Trends in Hyperuricemia A Lancet Rheumatology systematic review shows the prevalence of hyperuricaemia has risen markedly over the past two decades in both men and women, owing to population growth, aging, and increasing age-specific rates. https://t.co/8QAWkka0DM
Dr. John Cush @RheumNow( View Tweet )

Uric Acid: Is Lower Better?

Lowering serum urate and urate crystals in the body is indispensable for long-term management of gout. The pathophysiology is simple and powerful: no urate crystals, no gout flares. However, this simplicity in goal belies a nuanced consideration in management: how low should serum

Read Article
RT @aurelierheumo A long release version of xanthine oxidase inhibitor in gout -442 pts 36 wks -HR091506 vs febuxostat -SUA <300 μmol/L: 63.8% vs 40.7% (Δ +22.9%, p<0.0001) -higher SUA reduction vs baseline -Similar overall TEAEs (~90%) A molecule to keep an eye on! #LB0008

Dr. John Cush @RheumNow( View Tweet )

ICYMI: Worldwide Trends in Hyperuricemia

A Lancet Rheumatology systematic review shows the prevalence of hyperuricaemia has risen markedly over the past two decades in both men and women, owing to population growth, aging, and increasing age-specific rates

Read Article

Throughout Gout Campaign Month, RheumNow is bringing together internationally recognized experts to explore the Systemic Burden of Gout through Rx Updates, QD Clinic case discussions, and expert Vlogs designed for practicing rheumatologists. New educational content will release https://t.co/ZOQQuZinQd

Dr. John Cush @RheumNow( View Tweet )

EULAR26 Insights into Gout and Obesity

EurekAlert!

New EULAR 2026 data show continued treat-to-target ULT beats a discontinuation strategy for maintaining gout remission (79.2% vs. 62.9% flare-free), though many who stopped still stayed flare-free. A companion study links gout and rheumatoid arthritis to distinct, adverse body fat patterns tied

Read Article

EULAR 2026: Updated Recommendations for Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases

This update includes new pandemic era evidence, recombinant zoster vaccine data, and new perspectives on vaccination in patients taking novel immunosuppressants. Five overarching principles and 10 vaccine recommendations follow.

Read Article

Late-Breaking Studies at EULAR 2026

MedPage Today

Late-breaking abstracts presented at the European Alliance of Associations for Rheumatology's (EULAR) annual meeting, held here last week, addressed a wide range of clinical

Read Article
Gout and ULT Withdrawal -- The GO TEST FINALE Trial Professor Noortje van Herwaarden reviews abstract OP001 at EULAR 2026 in London https://t.co/d8U1168SRn https://t.co/hP0EUrciTu
Dr. John Cush @RheumNow( View Tweet )
Extended-release febuxostat (HR091506) vs standard febuxostat in gout. 442 patients, 36 weeks. SUA <300 μmol/L at Week 36: 63.8% vs 40.7% (p<0.0001) A 23% difference on the most stringent urate target. Well tolerated and acceptable safety profile Abstr LB0008 @RheumNow https://t.co/PSrn7K5BVS
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
#EULAR2026 LB0008 Phase 3 RCT in China of pts with high urate (SUA) & 2 gout flares within last year (N=142), HR091506, an extended formulation release of Febuxostat to prolong response was superior to Febuxostat at WK36. Unclear if will proceed to regulatory submission @RheumNow https://t.co/9lcVEzcxc1
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
New Insights in Gout Clinical Management https://t.co/Eo63NUhaY2 https://t.co/oHZG1c1LhL
Dr. John Cush @RheumNow( View Tweet )
Weight management should be discussed!! Obesity management will help rheumatic diseases. EULAR guidelines below. No ACR ones exist. Best evidence in OA and Gout. #EULAR2026 plenary @RheumNow https://t.co/hBu4YeXZbu
Bella Mehta @bella_mehta( View Tweet )
ULT de-escalation in Gout: shall we do it? Short answer: No RCT 309 pts 24 mo Primary outcome remission last 6 mo 79.2% ULT continuation vs 62.9% discontinuation p=0.002 Flare incidence 12% vs 32% More NSAID/colchicine use after stopping ULT Stopping ULT = urate rises quickly & https://t.co/bYKr5axu46
Aurelie Najm @AurelieRheumo( View Tweet )

New Insights in Gout Clinical Management

EULAR – The European Alliance of Associations for Rheumatology – held its 2026 annual Congress in London, where gout was high on the agenda. Current guidelines recommend lifelong urate-lowering therapy (ULT) in a treat-to-target (T2T) strategy to maintain remission, although there

Read Article
Which of the following is NOT a complication of Gout?

Dr. John Cush @RheumNow( View Tweet )

WSJ: Nurse Practitioner Is Now the Hottest Job in Healthcare

The Wall St. Journal has published a perspective on nurse practitioners (NP) and their very promising careers.

The U.S. healthcare system is undergoing a

Read Article

Quiz Talk (5.22.2026)

Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.

Read Article
Meet the RheumNow #EULAR2026 Reporting Team Delivering real-time insights from the forefront of rheumatology: 🩺 Dr. Antoni Chan (@synovialjoints) 🩺 Dr. Mrinalini Dey (@DrMiniDey) 🩺 Dr. Jiha Lee (@JihaRheum) 🩺 Dr. Aurelie Najm (@AurelieRheumo) 🩺 Dr. Janet Pope https://t.co/zpIeGWpL6P
Dr. John Cush @RheumNow( View Tweet )
Dr. Robert Terkeltaub walks through the evolution of gout at #RheumNowLive 2026. 🎧 Listen here: https://t.co/S6RXQo2Umt #Gout #Rheumatology #MedEd https://t.co/XDbTmj3MOw
Dr. John Cush @RheumNow( View Tweet )
×